AAC Capital takes over shares in Fysius Back Clinics from Gilde Healthcare - Gilde Healthcare

AAC Capital takes over shares in Fysius Back Clinics from Gilde Healthcare

June 14, 2018

Gilde Healthcare has announced that they have transferred their shares in the physiotherapy chain Fysius Back Clinics to AAC Capital. With the support of Gilde Healthcare, Fysius has grown into a national chain with 29 locations specialized in back care.

Fysius is a chain of treatment centers specializing in the treatment of back, neck and pelvic complaints. The company stands out for its science-based treatment protocol performed by specialized physiotherapists with personal treatment plans and specialist treatment equipment. Gilde Healthcare has worked with Fysius since 2011, when Fysius had 13 branches and was looking for growth capital to expand on a national level. Together with the management, Gilde developed the company into the largest specialist physiotherapy provider, with 29 branches and over 175 employees.

IT has played a significant role in the growth of Fysius. “We are one of the first primary healthcare providers to operate entirely digitally and use modern analysis techniques to continually improve healthcare for our customers,” says Eline Termaat, CEO of Fysius. “Each year, we treat over 35,000 clients and analyze this data in order to improve our protocols and service provision as well. This helps us to provide demonstrably better healthcare for lower back-related pain, which is what our customers are looking for.”

The collaboration between Gilde Healthcare and Fysius has run according to plan. “We have successfully implemented the transformation into a specialist physiotherapy chain with a science-based treatment protocol in back care. Now is a good time for Gilde to pass on the baton. Fysius is ready for the next growth phase,” says Hugo de Bruin, partner at Gilde Healthcare.

Maurice Bronckers, Managing Partner at AAC Capital, says: “We are delighted to have the opportunity to invest in Fysius in collaboration with Eline Termaat. Fysius really have proved themselves as a specialist in the treatment of back complaints in the Netherlands. We are looking forward to working together with Eline and the rest of her management team to enable Fysius to grow further.”

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
November 25, 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
October 30, 2024